Achieve Life Sciences (ACHV) Total Current Liabilities (2010 - 2026)

Achieve Life Sciences has disclosed Total Current Liabilities across 17 years of filings, most recently posting $11.8 million for Q1 2026.

• Quarterly Total Current Liabilities rose 65.96% year-over-year to $11.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.8 million (up 65.96% YoY) and the FY2025 annual result came in at $9.1 million, up 35.92% from the prior year.
• Total Current Liabilities grew to $11.8 million in Q1 2026, from $9.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $21.6 million in Q4 2022 and troughed at $3.4 million in Q2 2023.
• A 5-year average of $10.6 million and a median of $8.6 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities soared 406.26% — and 2024, when it sank 67.9%.
• Tracing ACHV's Total Current Liabilities over 5 years: stood at $21.6 million in 2022, then decreased by 3.64% to $20.8 million in 2023, then plunged by 67.9% to $6.7 million in 2024, then jumped by 35.92% to $9.1 million in 2025, then jumped by 30.29% to $11.8 million in 2026.
• Business Quant data shows ACHV's Total Current Liabilities at $11.8 million in Q1 2026, $9.1 million in Q4 2025, and $9.7 million in Q3 2025.